Hot Small Cap Stocks To Own For 2019


Opiates are incredibly potent pain relievers forpatients with severe traumatic pain or dealing with end-of-life care, but they are also being increasingly abused. Robert Brooke, the CEO of small cap Vitality Biopharma, Inc. (OTCQB: VBIO), which is dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, has recently written an article entitled: What We Should Know About Opiates and Prescription Drug Abuse.

In the article, Brooke noted a number of interesting statistics about opiates and opiate abuse:

Last year, there were 47,055 Americans that died from drug overdoses, and opioids were involved in 61% of these cases. Since 2013, the rates of drug-overdose deaths have exceeded the number of deaths from car accidents. The U.S. uses 80% of the worlds opioids, while representing only 4.6% of the worlds population. In a movement towards aggressive management of pain, there has been a 10-fold increase in the medical use of opioids in the last 20 years. More than 2.4 million Americans now have a severe opioid-use disorder, which includes dependence on heroin and also prescription opiate drugs that are known by many names. Studies have shown that today about 75% to 86% of heroin users started with prescription opioid pain relievers. A 2012 Canadian study showed that 22% of people who were prescribed opioids by their doctors for long-term pain management started abusing the pills. An estimated 40% of older adults live with chronic pain. Roughly 70% of patients now regularly receive opiates upon hospitalization.


Brooke goes on to write:

Hot Small Cap Stocks To Own For 2019: China Metro-Rural Holdings Limited(CNR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of Canadian National Railway (TSE:CNR) (NYSE:CNI) have been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is C$109.36.

  • [By Max Byerly]

    Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

  • [By Stephan Byrd]

    Brokerages expect Canadian National Railway (NYSE:CNI) (TSE:CNR) to announce earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings of $1.00 per share in the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, July 24th.

  • [By Shane Hupp]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

Hot Small Cap Stocks To Own For 2019: Petroquest Energy Inc(PQ)


Advisors’ Opinion:

  • [By Ethan Ryder]

    News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Hot Small Cap Stocks To Own For 2019: FuelCell Energy Inc.(FCEL)


Advisors’ Opinion:

  • [By Peter Graham]

    Small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) reported Q4 and fiscal year ended October 31, 2017 earningswithQ4 total revenuesbeing $47.9 million versus $24.5 million:

  • [By Paul Ausick]

    FuelCell Energy Inc. (NASDAQ: FCEL) posted a decrease of 4% in short interest during the period. Some 7.42 million shares were short as of June 15. The stock closed at $1.37 on Tuesday, down about 1.4% for the day, in a 52-week range of $1.18 to $2.49. Shares traded down more than 10% in the short interest period, and days to cover dropped from 17 to six.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on FuelCell Energy (FCEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Small Cap Stocks To Own For 2019: Achillion Pharmaceuticals Inc.(ACHN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Skeptics might deride a comparison of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) as an exercise in finding the biggest loser. Both companies continue to post huge net losses every quarter, and their stocks are down by at least 30% over the last 12 months.

  • [By Stephan Byrd]

    Achillion Pharmaceuticals (NASDAQ:ACHN) has been given an average recommendation of “Hold” by the nine brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.20.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Leave a Reply

Your email address will not be published.